Shuo-feng Yuan - Infectious Diseases

Author Information

Shuo-feng Yuan is a distinguished researcher affiliated with the State Key Laboratory of Emerging Infectious Diseases at The University of Hong Kong, situated in Pokfulam, Hong Kong Special Administrative Region, China. Dr. Yuan's work is primarily focused on the field of infectious diseases, where he has made significant contributions to the understanding and management of various viral infections.

Research Contributions

Dr. Shuo-feng Yuan has an extensive research portfolio that spans various aspects of infectious diseases, particularly focusing on viral pathogenesis and therapeutic interventions. Throughout 2022, Dr. Yuan contributed to critical studies on COVID-19, including exploring the role of ACE2 in viral infections, developing innovative diagnostic assays, and investigating potential therapeutic strategies against SARS-CoV-2 variants. His work also extends to studying the mechanisms of virus transmission and immune responses, as indicated by his research on animal-to-human transmission of the SARS-CoV-2 Delta variant and the development of live attenuated vaccines.

Aliases

Shuo-feng Yuan is also known by the alias Shuofeng Yuan, which may appear in various publications and academic contexts.

Publication and Citation Metrics

Metric	Value
Total Citation Count	18,987
H-index	38
Paper Count	151

Publications:

Phenethylamine-producing gut bacteria induces diarrhea-predominant irritable bowel syndrome by increasing serotonin biosynthesis

DOI: 10.1101/2022.03.05.483096

Year: 2022

Angiotensin converting enzyme 2 (ACE2): Virus accomplice or host defender

DOI: 10.1101/2022.03.06.483197

Year: 2022

hnRNP C modulates MERS-CoV and SARS-CoV-2 replication by governing the expression of a subset of circRNAs and cognitive mRNAs

DOI: 10.1080/22221751.2022.2032372

Year: 2022

COVID-19 in Joint Ageing and Osteoarthritis: Current Status and Perspectives

DOI: 10.3390/ijms23020720

Year: 2022

Multiplex metal-detection based assay (MMDA) for COVID-19 diagnosis and identification of disease severity biomarkers

DOI: 10.1039/d1sc05852e

Year: 2022

Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration

DOI: 10.1016/j.ijpharm.2022.121704

Year: 2022

Orally administered bismuth drug together with N-acetyl cysteine as a broad-spectrum anti-coronavirus cocktail therapy

DOI: 10.1039/d1sc04515f

Year: 2022

Probable Animal-to-Human Transmission of SARS-CoV-2 Delta Variant AY.127 Causing a Pet Shop-Related COVID-19 Outbreak in Hong Kong

DOI: 10.1093/cid/ciac171

Year: 2022

Enhanced trimeric ACE2 exhibits potent prophylactic and therapeutic efficacy against the SARS-CoV-2 Delta and Omicron variants in vivo

DOI: 10.1038/s41422-022-00656-4

Year: 2022

Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals

DOI: 10.1038/s41423-022-00855-4

Year: 2022

When Should You See a Doctor?

How Can Zoonotic Diseases be Prevented?

How Are Infectious Disease-Related Headaches Diagnosed?

What Are Some Key Infectious Disease Research Initiatives by the NIH?

How is Measles Diagnosed?

How Do B Cells Recognize Pathogens?

Can the Immune System Overreact?

What are Aedes Mosquitoes?

What is Viral Mutation and Why is it Important?

How Does Direct Contact Transmission Occur?

Partnered Content Networks

Relevant Topics